Amatuximab and novel agents targeting mesothelin for solid tumors
| Autor: | Sara Cecco, Paolo Baldo |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
medicine.drug_class Amatuximab Review Monoclonal antibody Metastasis 03 medical and health sciences antigen 0302 clinical medicine Pancreatic cancer Medicine Pharmacology (medical) Mesothelin amatuximab Mesothelioma Lung cancer biology target therapy business.industry mesothelin medicine.disease 030104 developmental biology Oncology monoclonal antibody mesothelioma 030220 oncology & carcinogenesis Cancer research biology.protein business Ovarian cancer |
| Zdroj: | OncoTargets and therapy |
| ISSN: | 1178-6930 |
| DOI: | 10.2147/ott.s145105 |
| Popis: | Mesothelin (MSLN) is considered a promising target for cancer therapy. Originally extracted in 1992 after the immunization of mice with a human ovarian cancer (OC) cell line and cloned in 1996, MSLN seems to be involved in cell adhesion and metastasis. MSLN is prevalent in mesothelia tissues but is expressed in several human cancers, such as OC, pancreatic cancer, mesothelioma, and lung cancer. Amatuximab (MORAb-009) is a mouse-human chimeric monoclonal antibody with a selective affinity for MSLN. The principal mechanism of action comprises inhibition of binding of MSLN with the antigen CA125/MUC16. The highest phase of development is actually a Phase II trial (MORAb-009-201, Europe). In this review, we describe the mechanism of action of amatuximab and other MSLN-targeting novel drugs, along with a discussion about the expected efficacy, safety, and toxicity of this promising group of agents and implications for future research and clinical practice. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|